Senores Pharmaceuticals Complete Financial Statements

In FY2025, Senores Pharmaceuticals (SENORES) reported revenue ₹159 Cr, net profit ₹30 Cr and EPS ₹6.54, with a net profit margin of 18.9% and ROE of 3.7%. Full financial statements from FY2022 to FY2025 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see SENORES company profile.

4 Years of Data
2025 - 2022

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 18.87% 2025 data
EBITDA Margin 29.56% 2025 data
Operating Margin 27.00% 2025 data
Return on Assets 2.44% 2025 data
Return on Equity 3.69% 2025 data

Balance Sheet Ratios

Current Ratio 4.15 2025 data
Equity Ratio 66.18% 2025 data
Asset Turnover 0.13 2025 data

SENORES Revenue, Net Profit & EBITDA — Year-on-Year Growth

SENORES YoY (Sept 2024 vs Sept 2025) — revenue +59.0%, net profit +130.8%, EBITDA +104.3%, expenses +45.5%.

Revenue Growth
+59.0%
Year-over-Year
Net Profit Growth
+130.8%
Year-over-Year
EBITDA Growth
+104.3%
Year-over-Year
Expense Growth
+45.5%
Year-over-Year
Assets Growth
+97.3%
Year-over-Year
Equity Growth
+250.0%
Year-over-Year
Operating Cash Flow Growth
-76.9%
Year-over-Year
Investing Cash Flow Growth
-696.3%
Year-over-Year
Financing Cash Flow Growth
+558.6%
Year-over-Year

SENORES Income Statement — Revenue, EBITDA & Net Profit

Senores Pharmaceuticals revenue ₹159 Cr, EBITDA ₹47 Cr, net profit ₹30 Cr, EPS ₹6.54 (2025) — net profit margin 18.9%. Explore SENORES Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Dec 2023
Revenue 159 117 134 169 100 104 80 108 80
Expenses 112 95 104 121 77 80 59 77 64
EBITDA 47 22 30 48 23 24 21 31 16
Operating Profit Margin % 27.00% 10.00% 20.00% 27.00% 21.00% 22.00% 26.00% 25.00% 19.00%
Depreciation 8 5 6 8 4 4 4 4 3
Interest 6 5 5 5 5 3 5 6 3
Profit Before Tax 41 21 27 45 16 18 14 21 10
Tax 11 3 5 11 3 3 3 4 3
Net Profit 30 18 21 34 13 14 11 16 7
Earnings Per Share (₹) 6.54 3.81 4.60 7.29 3.92 8.03 3.39 5.04 4.01

SENORES Balance Sheet — Assets, Liabilities & Shareholders' Equity

SENORES total assets ₹1,227 Cr, total equity ₹812 Cr, total liabilities ₹ Cr (2025) — ROE 3.7%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022
ASSETS
Total Assets 1,227 622 131 59
Current Assets 722 251 51 27
Fixed Assets 301 235 27 7
Capital Work in Progress 173 97 35 8
Investments 0 0 17 15
Other Assets 754 289 53 29
LIABILITIES
Total Liabilities
Current Liabilities 174 143 34 13
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 812 232 46 37
Share Capital 46 31 10 9
Reserves & Surplus 740 174 36 28

SENORES Cash Flow Statement — Operating, Investing & Financing

Senores Pharmaceuticals operating cash flow ₹-46 Cr, investing ₹-430 Cr, financing ₹573 Cr, net cash flow ₹98 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022
Operating Activities -46 -26 -1 -10
Investing Activities -430 -54 -48 -24
Financing Activities 573 87 46 37
Net Cash Flow 98 8 -3 2